MTORC1/2 Inhibition as a Therapeutic Strategy for PIK3CA Mutant Cancers.

ABSTRACT: PIK3CA mutations are common in clinical molecular profiling, yet an effective means to target these cancers has yet to be developed. MTORC1 inhibitors are often used off-label for patients with PIK3CA mutant cancers with only limited data to support this approach. Here we describe a cohort of patients treated with cancers possessing mutations activating the PI3K signaling cascade with minimal benefit to treatment with the MTORC1 inhibitor everolimus. Previously, we demonstrated that dual PI3K/mTOR inhibition could decrease proliferation, induce differentiation, and result in a treatment response in APC and PIK3CA mutant colorectal cancer. However, reactivation of AKT was identified, indicating that the majority of the benefit may be secondary to MTORC1/2 inhibit

SUBMITTER: Fricke SL 

PROVIDER: S-EPMC6363831 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature